Busardò, FP, Gottardi, M, Tini, A, et al. Replacing GHB with GBL in recreational settings: a new trend in chemsex. Curr Drug Metab 2018;19(13):1080–1085. https://doi.org/10.2174/1389200219666180925090834CrossRefGoogle ScholarPubMed

See for example Castro AL, , Dias AS, Melo P, Tarelho S, , Franco JM, , Teixeira HM., Quantification of GHB and GHB-GLUC in an 1,4-butanediol intoxication: a case report. Forensic Sci Int 2019;297:378–382. https://doi.org/10.1016/j.forsciint.2019.01.035Google Scholar

Stefani M, , Roberts DM., 1,4-Butanediol overdose mimicking toxic alcohol exposure. Clin Toxicol 2020;58(3):204–207. https://doi.org/10.1080/15563650.2019.1617419Google Scholar

Office for National Statistics. Deaths Related to Drug Poisoning in England and Wales, 2013 (Statistical Bulletin). Home Office, September 2014.Google Scholar

Advisory Council on the Misuse of Drugs (ACMD). GBL and 1,4-BD: Assessment of Risk to the Individual and Communities in the UK. Published 2008.Google Scholar

Palatini, P, Tedeschi, L, Frison, G, Padrini, R, Zordan, R, Orlando, R, et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993;45:353–356.Google Scholar

Borgen, LA, Okerholm, R, Morrison, D, Lai, A. The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J Clin Pharmacol 2003;43:59–65.CrossRefGoogle ScholarPubMed

Brenneisen, R, Elsohly, MA, Murphy, TP, Passarelli, J, Russmann, S, Salamone, SJ, et al. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 2004;28:625–630.CrossRefGoogle ScholarPubMed

Helrich, M, Mcaslan, TC, Skolnik, S, Bessman, SP. Correlation of blood levels of 4-hydroxybutyrate with state of consciousness. Anesthesiology 1964;25:771–775.Google Scholar

Abanades, S, Farre, M, Segura, M, Pichini, S, Barral, D, Pacifici, R, et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann NY Acad Sci 2006;1074:559–576.Google Scholar

Brailsford, AD, Cowan, DA, Kicman, AT. Pharmacokinetic properties of g-hydroxybutyrate (GHB) in whole blood, serum, and urine. J Anal Toxicol 2012;36(2):88–95. https://doi.org/10.1093/jat/bkr023Google Scholar

Schep, LJ, Knudsen, K, Slaughter, RJ, Vale, JA, Mégarbane, B. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol. Clin Toxicol 2012;50(6):458–470. https://doi.org/10.3109/15563650.2012.702218Google Scholar

González, A, Nutt, D. Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol. 200;519(2):195–204.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the Risk Assessment of GHB in the Framework of the Joint Action on New Synthetic Drugs. Published 2002.Google Scholar

Carter LP, , Chen W, Wu H, et al. Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV). Drug Alcohol Depend 2005;78(1):91–99.Google Scholar

Bessman, SP, Fishbein, WN. Gamma-hydroxybutyrate, a normal brain metabolite. Nature 1963;200:1207–1208.CrossRefGoogle ScholarPubMed

Poldrugo, F, Snead, OC. 1,4-butanediol and ethanol compete for degradation in rat brain and liver in vitro. Alcohol 1986;3(6):367–370.Google Scholar

Poldrugo, F, Snead, OC. 1,4-butanediol, gamma-hydroxybutyric acid and ethanol: relationships and interactions. Neuropharmacology 1984;23(1):109–113.Google Scholar

Quang, LS, Desai, MC, Shannon, MW, Woolf, AD, Maher, TJ. 4-methylpyrazole decreases 1,4-butanediol toxicity by blocking its in vivo biotransformation to gamma-hydroxybutyric acid. Ann NY Acad Sci 2004;1025:528–537.Google Scholar

Carter LP, , Chen W, Wu H, et al.Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV). Drug Alcohol Depend 2005;78(1):91–99.Google Scholar

Dijkstra BAG, Kamal R, van Noorden MS, , de Haan H, , Loonen AJM, De Jong CAJ., Detoxification with titration and tapering in gamma-hydroxybutyrate (GHB) dependent patients: The Dutch GHB monitor project. Drug Alcohol Depend (online) 2017:170164–170173. https://doi.org/10.1016/j.drugalcdep.2016.11.014Google Scholar

Xu X-M, , Wei Y-D, , Liu Y, , Li Z-X., Gamma-hydroxybutyrate (GHB) for narcolepsy in adults: an updated systematic review and meta-analysis. Sleep Med 2019;64: 62–70. https://doi.org/10.1016/j.sleep.2019.06.017Google Scholar

Craig, K, Gomez HF, McManus JL, Bania TC. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000;18:65–70.Google Scholar

Nicholson, KL, Balster, RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend 2001;63:1–22.Google Scholar

Grela A, , Gautam L, , Cole MD., A multifactorial critical appraisal of substances found in drug-facilitated sexual assault cases. Forensic Sci Int 2018;292:50–60. https://doi.org/10.1016/j.forsciint.2018.08.034Google Scholar

See www.medicinescomplete.com/mc/bnf/current/PHP2146-sodium-oxybate.htm; www.medicines.org.uk/emc/medicine/17364/SPC/Xyrem+500+mg+ml+oral+solution; www.xyrem.com/images/Xyrem_Med_Guide.pdf; as well as the manufacturer’s website.Google Scholar

Bertol E, , Di Milia MG, , Fioravanti A, et al. Proactive drugs in DFSA cases: toxicological findings in an eight-years study. Forensic Sci Int 2018;291:207–215.CrossRefGoogle Scholar

Busardò FP, , Varì MR, , Di Trana A, , Malaca S, , Carlier J, , Di Luca NM., Drug-facilitated sexual assaults (DFSA): a serious underestimated issue. Eur Rev Med Pharmacol Sci 2019;23:10577–10587.Google Scholar

Pettigrew, M. Somnophilia and sexual abuse through the administration of GHB and GBL. J Forensic Sci 2019;64(1):302–303. https://doi.org/10.1111/1556-4029.13812CrossRefGoogle ScholarPubMed

Paul, A, Mahesan, A. Date rape drugs in Las Vegas: detection after the fact. Obstet Gynecol 2019;133:98S. https://doi.org/10.1097/01.AOG.0000558790.02961.d9CrossRefGoogle Scholar

Varela M, , Nogue S, , Oro M., Gamma hydroxybutyrate use for sexual assault. Miro Emerg Med J 2004;21:255–256. https://doi.org/10.1136/emj.2002.002402Google Scholar

Kapitány-Fövény M, , Zacher G, , Posta J, , Demetrovics Z., GH B-involved crimes among intoxicated patients. Forensic Sci Int 2017;275:23–29. https://doi.org/10.1016/j.forsciint.2017.02.028Google Scholar

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). GHB and Its Precursor GBL: An Emerging Trend Case Study (Thematic Paper). Published 2008. Available at: www.emcdda.europa.eu/system/files/publications/505/TP_GHB_and_GBL_107300.pdf [last accessed 19 February 2022].Google Scholar

van Noorden, MS, Mol, T, Wisselink, J, Kuipers, W, Dijkstra, BAG. Treatment consumption and treatment re-enrollment in GHB-dependent patients in the Netherlands. Drug Alcohol Depend 2017;176:96–101.Google Scholar

Kamal, RM, van Noorden, MS, Wannet, W, Beurmanjer, H, Dijkstra, BA, Schellekens, A. Pharmacological treatment in γ-hydroxybutyrate (GHB) and γ-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs 2017;31(1):51–64.Google Scholar

Heliodore, C, Malissin, I, Megarbane, B, Gourlain, H, Labat, L. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) poisonings admitted to the ICU: features and usefulness of plasma GHB concentration measurement. Clin Toxicol 2019;57(6);472. https://doi.org/10.1080/15563650.2019.1598646.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Publications Office of the European Union, Luxembourg, 2019.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Publications Office of the European Union, Luxembourg, 2019.Google Scholar

Miró, Ò, Galicia, M, Dargan, P, et al. Intoxication by gamma hydroxybutyrate and related analogues: clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse. Toxicol Lett 2017;277:84–91. https://doi.org/10.1016/j.toxlet.2017.05.030Google Scholar

Sumnall, H, Woolfalla, K, Edward, S, Cole, J, Beynon, C. Use, function, and subjective experiences of gammahydroxybutyrate (GHB). Drug Alcohol Depend 2008;92(1–3):286–290.Google Scholar

Degenhardt, L, Darke, S, Dillon, P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend 2002;67(1):89–94.Google Scholar

Guasp A. Gay and Bisexual Men’s Health Survey. Stonewall 2012.Google Scholar

Wood, DM, Measham, F, Dargan, PI. ‘Our favourite drug’: prevalence of use and preference for mephedrone in the London night-time economy 1 year after control. J Substance Use 2012;17(2):91–97. https://doi.org/10.3109/14659891.2012.661025Google Scholar

Measham, F, Wood, DM, Dargan, PI, Moore, KA. The rise of legal highs: prevalence and patterns in the use of illegal drugs and first- and second-generation ‘legal highs’ in south London gay dance clubs. J Substance Use 2011;16(40):263–272.CrossRefGoogle Scholar

Halkitis, PN, Palamar, JJ. GHB use among gay and bisexual men. Addict Behav 2006;31:2135–2139.Google Scholar

Giorgetti R, , Tagliabracci A, , Schifano F, , Zaami S, , Marinelli E, , Busardò FP., When ‘chems’ meet sex: a rising phenomenon called ‘chemsex’. Curr Neuropharmacol 2017;15(5): 762–770.Google Scholar

Hibbert, MP, Brett, CE, Porcellato, LA, Hope, VD. Psychosocial and sexual characteristics associated with sexualised drug use and chemsex among men who have sex with men (MSM) in the UK. Sex Transm Infect 2019;95(5):1368–4973.Google Scholar

Trombley TA, , Capstick RA, , Lindsle CW., DARK classics in chemical neuroscience: gamma-hydroxybutyrate (GHB). ACS Chem Neurosci 2019 (online). https://doi.org/10.1021/acschemneuro.9b00336Google Scholar

Hammoud, MA, Bourne, A, Maher, L, et al. Intensive sex partying with gamma-hydroxybutyrate: factors associated with using gamma-hydroxybutyrate for chemsex among Australian gay and bisexual men – results from the Flux Study. Sex Health 2018;15(2):123–134. https://doi.org/10.1071/SH17146CrossRefGoogle ScholarPubMed

Joyce N, , MacNeela P, , Sarma K, , Ryall G, , Keenan E., The experience and meaning of problematic ‘G’ (GHB/GBL) use in an Irish context: an interpretative phenomenological analysis. Int J Ment Health Addict 2018;16:1033–1054. https://doi.org/10.1007/s11469-017-9851-yGoogle Scholar

Giorgetti, R, Tagliabracci, A, Schifano, F, Zaami, S, Marinelli, E, Busardò, FP. When chems meet sex: a rising phenomenon called ChemSex. Curr Neuropharmacol 2017;15(5):762–770.Google Scholar

Bell, J, Gamma-butyrolactone, Collins R. (GBL) dependence and withdrawal. Addiction 2011;106(2):442–447. https://doi.org/10.1111/j.1360-0443.2010.03145.xGoogle Scholar

Grund J-P, , de Bruin D, , Van Gallen S., Going knock: recurrent comatose GHB intoxication in the Netherlands. Int J Drug Policy 2018;58:137–148.Google Scholar

Evans, R, Sayal, K. Gammabutyrolactone: withdrawal syndrome resembling delirium tremens. J Substance Use 2012;17(4):384–387.Google Scholar

Miotto, K, Darakjian, J, Basch, J, Murray, S, Zogg, J, Rawson, R. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001;10(3):232–241.Google Scholar

de Jong, CA, Kamal, R, Dijkstra, BA, de Haan, HA. Gamma-hydroxybutyrate detoxification by titration and tapering. Eur Addict Res 2012;18(1):40–45. https://doi.org/10.1159/000333022Google Scholar

Herold, AH, Sneed, KB. Treatment of a young adult taking gamma-butyrolactone (GBL) in a primary care clinic. J Am Board Fam Pract 2002;15(2):161–163.Google Scholar

Drug Enforcement Agency.Google Scholar

Couper, FJ, Marinetti, LJ. Gamma-hydroxybutyrate (GHB) – effects on human performance and behavior. Forensic Sci Rev 2002;14(1):101–121.Google Scholar

McDonough, M, Kennedy, N, Glasper, A, Bearn, J. Clinical features and management of gamma- hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004; 75:3–9.CrossRefGoogle ScholarPubMed

Chew, G, Fernando, A. Epileptic seizure in GHB withdrawal. Australas Psychiatry 2004;12:410–411.CrossRefGoogle ScholarPubMed

Sivilotti, MLA, Burns, MJ, Aaron, CK, Greenberg, MJ. Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med 2001;38:660–665.CrossRefGoogle ScholarPubMed

Kam, P, Yoong, F. Gamma-hydroxybutyric acid: an emerging recreational drug. Anaesthesia 1998;53:1195–1198.Google Scholar

Abanades, S, Farré, M, Barral, D, Torrens, M, Closas, N, Langohr, K, et al. Relative abuse liability of [gamma]-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J Clin Psychopharmacol 2007;27(6):625–638.Google Scholar

Galicia, M, Nogue, S, Miro, O. Liquid ecstasy intoxication: clinical features of 505 consecutive emergency department patients. Emerg Med J 2011;28(6):462–466. https://doi.org/10.1136/emj.2008.068403Google Scholar

Luby, S, Jones, J, Zalewski, A. GHB use in South Carolina. Am J Public Health 1992;82(1):128.CrossRefGoogle ScholarPubMed

Henderson, DL, Ginsberg, JP. Withdrawal, recovery, and long-term sequelae of gamma- butyrolactone dependence: a case report. Am J Addict 2008;17(5):456–457. https://doi.org/10.1080/10550490802266193Google Scholar

Zvosec, DL, Smith, SW. Agitation is common in gamma-hydroxybutyrate toxicity. Am J Emerg Med 2005;23(3):316–320.Google Scholar

Oliveto, A, Gentry, WB, Pruzinsky, R, et al. Behavioral effects of gamma-hydroxybutyrate in humans. Behav Pharmacol 2010;21(4):332–342. https://doi.org/10.1097/FBP.0b013e32833b3397Google Scholar

Stein, LA, Lebeau, R, Clair, M, et al. A web-based study of gamma hydroxybutyrate (GHB): patterns, experiences, and functions of use. Am J Addict 2011;20(1):30–39. https://doi.org/10.1111/j.1521-0391.2010.00099.xGoogle Scholar

Kapitány-Fövény M, , Mervó B, , Corazza O, et al. Enhancing sexual desire and experience: an investigation of the sexual correlates of gamma-hydroxybutyrate (GHB). Hum Psychopharmacol Clin Exp 2015;30:276–284. https://doi.org/10.1002/hup.2491CrossRefGoogle Scholar

Bourne, A, Reid, D, Hickson, F, Torres-Rueda, S, Weatherburn, P. Illicit drug use in sexual settings (‘chemsex’) and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study. Sex Transm Infect (online). https://doi.org/10.1136/sextrans-2015-052052Google Scholar

Daskalopoulou, M, Rodger, A, Thornton, A, et al. Sexual behaviour, recreational drug use and hepatitis C co-infection in HIV-diagnosed men who have sex with men in the United Kingdom: results from the ASTRA study. J Int AIDS Soc 2014b;17(4 Suppl. 3). https://doi.org/10.7448/IAS.17.4.19630CrossRefGoogle ScholarPubMed

Colfax, GN, Mansergh, G, Guzman, R, et al. Drug use and sexual risk behaviour among gay and bisexual men who attend circuit parties: a venue-based comparison. J Acquir Immune Defic Syndr 2001;28(4):373–379.Google Scholar

Mattison, AM, Ross, MW, Wolfson, T, Franklin, D, San Diego HIV Neurobehavioral Research Center Group. Circuit party attendance, club drug use and unsafe sex in gay men. J Subst Abuse 2001;13(1–2):119–126.Google Scholar

Keogh, P, Reid, D, Bourne, A, et al. Wasted Opportunities: Problematic Alcohol and Drug Use Among Gay Men and Bisexual Men. Sigma Research, 2009. Available at: http://sigmaresearch.org.uk/files/report2009c.pdf [last accessed 19 February 2022].Google Scholar

Hammoud, MA, Bourne, A, Maher, L, et al. Intensive sex partying with gamma-hydroxybutyrate: factors associated with using gamma-hydroxybutyrate for chemsex among Australian gay and bisexual men – results from the Flux Study. Sex Health 2018;15(2):123–134. https://doi.org/10.1071/SH17146Google Scholar

Bourne A, , Ong, J, Pakianathan, M. Sharing solutions for a reasoned and evidence-based response: chemsex/party and play among gay and bisexual men. Sex Health 2018;15:99–101. https://doi.org/10.1071/SH18023Google Scholar

O’Reilly M., Chemsex case study: is it time to recommend routine screening of sexualised drug use in men who have sex with men? Sex Health 2018;15(2):167–169. https://doi.org/10.1071/SH17156Google Scholar

Bourne A, Reid D, Hickson F, Torres-Rueda S, Weatherburn P. Illicit drug use in sexual settings (‘chemsex’) and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study. Sex Transm Infect 2015;91(8):564–568.Google Scholar

Advisory Council on the Misuse of Drugs: An assessment of the harms of gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and closely related compounds. Published 2020.Google Scholar

Schep, LJ, Knudsen, K, Slaughter, RJ, Vale, JA, Mégarbane, B. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol. Clin Toxicol 2012;50(6):458–470. https://doi.org/10.3109/15563650.2012.702218Google Scholar

Caldicott, DG, Chow, FY, Burns, BJ, Felgate, PD, Byard, RW. Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia. Med J Aust 2004;181:310–313.Google Scholar

Couper, FJ, Thatcher, JE, Logan, BK. Suspected GHB overdoses in the emergency department. J Anal Toxicol 2004;28:481–484.Google Scholar

Corkery, JM, Loi, B, Claridge, H, et al. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4 butanediol (1,4-BD; BDO): a literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev 2015 (online). http://dx.doi.org/10.1016/j.neubiorev.2015.03.012Google Scholar

Küting, T, Krämer, M, Bicker, W, Madea, B, Hess, C. Case report: another death associated to γ-hydroxybutyric acid intoxication. Forensic Sci Int 2019;299:34–40.Google Scholar

Corkery, JM, Loi, B, Claridge, H, et al. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4 butanediol (1,4-BD; BDO): a literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev (online) 2015. https://doi.org/10.1016/j.neubiorev.2015.03.012Google Scholar

National Programme on Substance Abuse Deaths (NPSAD). Drug-Related Deaths Reported by Coroners in England, Wales, Northern Ireland, Guernsey, Jersey and the Isle of Man; Police Forces in Scotland; and the Northern Ireland Statistics and Research Agency Annual Report 2013 on Deaths Between January–December 2012.Google Scholar

Darke S, , Peacock A, , Duflou J, , Farrell M, , Lappin J., Characteristics and circumstances of death related to gamma hydroxybutyrate (GHB). Clin Toxicol 2020 (online). https://doi.org/10.1080/15563650.2020.1726378Google Scholar

Hockenhulla J, , Murphy KG, , Paterson S. An observed rise in g-hydroxybutyrate-associated deaths in London: evidence to suggest a possible link with concomitant rise in chemsex. Forensic Sci Int 2017;270:93–97.Google Scholar

Corkery, JM, Loi, B, Claridge, H, Goodair, C, Schifano, F. Deaths in the lesbian, gay, bisexual and transgender United Kingdom communities associated with GHB and precursors. Curr Drug Metab 2017 (online). https://doi.org/10.2174/1389200218666171108163817Google Scholar

Chin, RL, Sporer, KA, Cullison, B, Dyer, JE, Wu, TD. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998;31(6):716–722.Google Scholar

Miróa O, , Galiciaa M, , Darganb P, et al. Euro-DEN Research Group: Intoxication by gamma hydroxybutyrate and related analogues: clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse. Toxicol Lett 2017;277(5):84–91. https://doi.org/10.1016/j.toxlet.2017.05.030Google Scholar

Morse BL, , Chadha GS, , Felmlee MA, , Follman KE, , Morris ME., Effect of chronic γ-hydroxybutyrate (GHB) administration on GHB toxicokinetics and GHB-induced respiratory depression. Am J Drug Alcohol Abuse 2017;43(6):686–693. https://doi.org/10.1080/00952990.2017.1339055Google Scholar

Gable, RS. Acute toxic effects of club drugs. J Psychoactive Drugs 2004;36(3):303–313.Google Scholar

Snead, OC, Gibson, KM. Gamma-hydroxybutyric acid. N Engl J Med 2005;352(26):2721–2732.Google Scholar

Li, J, Stokes, SA, Woeckener, A. A tale of novel intoxication: a review of the effects of gamma-hydroxybutyric acid with recommendations for management. Ann Emerg Med 1998;31:729–736.Google Scholar

Centers for Disease Control (CDC). Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate. Morb Mortal Wkly Rep 1990;39:861–863.Google Scholar

Vickers, MD. Gamma-hydroxybutyric acid. Int Anesthesiol Clin 1969;7:75–89.Google Scholar

Galloway, GP, Frederick, SL, Staggers, FE, et al. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 1997;92:89–96.Google Scholar

Grund JP, , de Bruin D, , van Gaalen S., Going knock: recurrent comatose GHB intoxication in the Netherlands. Int J Drug Policy 2018;58:137–148. https://doi.org/10.1016/j.drugpo.2018.06.010Google Scholar

Madah-Amiri D, , Myrmel L, , Brattebø G., Intoxication with GHB/GBL: characteristics and trends from ambulance-attended overdoses. Scand J Trauma Resusc Emerg Med 2017;25:98. https://doi.org/10.1186/s13049-017-0441-6Google Scholar

Schep, LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) 2012;50:458–470.Google Scholar

Korf, DJ, Nabben, T, Benschop, A, Ribbink, K, Van Amsterdam, JGC. Risk factors of γ-hydroxybutyrate overdosing. Eur Addict Res 2014;20:66–74.Google Scholar

Liechti, ME, Kunz, I, Greminger, P, Speich, R, Kupferschmidt, H. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend 2006;81:323–326.Google Scholar

Miró, Ò, Galicia, M, Dargan, P, et al. Intoxication by gamma hydroxybutyrate and related analogues: clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse. Toxicol Lett 2017;277:84–91.Google Scholar

Van Amsterdam, JGC, Brunt, TM, McMaster, MTB, Niesink, RJM. Possible long-term effects of γ-hydroxybutyric acid (GHB) due to neurotoxicity and overdose. Neurosci Biobehav Rev 2012;36:1217–1227.Google Scholar

Kapitány-Fövény M, , Mervó B, , Corazza O, et al. Enhancing sexual desire and experience: an investigation of the sexual correlates of gamma-hydroxybutyrate (GHB) use. Hum Psychopharmacol Clin Exp 2015;30:276–284. https://doi.org/10.1002/hup.2491Google Scholar

Nunez OF, Lopez, Rymer JA, , Tamama K, , Case of sudden acute coma followed by spontaneous recovery. J Appl Lab Med 2018;3(3):507–510. https://doi.org/10.1373/jalm.2017.025718Google Scholar

Korf, DJ, Nabben, T, Benschop, A, Ribbink, K, Van Amsterdam, JGC. Risk factors of γ-hydroxybutyrate overdosing. Eur Addict Res 2014;20:66–74.Google Scholar

Liechti, ME, Kunz, I, Greminger, P, Speich, R, Kupferschmidt, H. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend 2006;81:323–326.Google Scholar

Miró, Ò, Galicia, M, Dargan, P, et al. Intoxication by gamma-hydroxybutyrate and related analogues: clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse. Toxicol Lett 2017;277:84–91.Google Scholar

Miró, O, Nogué, S, Espinosa, G, To-Figueras, J, Sánchez, M. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol 2002;40(2):129–135.Google Scholar

Louagie, HK, Verstraete, AG, DeSoete, CJ, Baetens, DG, Calle, PA. A sudden awakening from a near coma after combined intake of gamma-hydroxybutyric acid (GHB) and ethanol. J Toxicol Clin Toxicol 1997;35:591–594.Google Scholar

Ingels, M, Rangan, C, Bellezzo, J, Clark, RF. Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med 2000;9(1):47–50.Google Scholar

Munir, VL, Hutton, JE, Harney, JP, Buykx, P, Weiland, TJ, Dent, AW. Gamma-hydroxybutyrate: a 30-month emergency department review. Emerg Med Australas 2008;20(6):521–530. https://doi.org/10.1111/j.1742- 6723.2008.01140.x.Google Scholar

Van Sassenbroeck, DK, De Neve, N, De Paepe, P, Belpaire, FM, Verstraete, AG, Calle, PA, et al. Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: a case series. Clin Toxicol 2007;45:533–538.Google Scholar

Liakoni E, , Walther F, , Nickel CH, , Liechti ME, . Presentations to an urban emergency department in Switzerland due to acute γ-hydroxybutyrate toxicity. Scand J Trauma Resusc Emerg Med 2016;24:107. https://doi.org/10.1186/s13049-016-0299-zGoogle Scholar

Madah-Amiri, D, Myrmel L, Brattebø G. Intoxication with GHB/GBL: characteristics and trends from ambulance-attended overdoses. Scand J Trauma Resusc Emerg Med 2017;25:98. https://doi.org/10.1186/s13049-017-0441-6Google Scholar

Madah‐Amiri D, Clausen T, Myrmel L, Brattebø G, Lobmaier P. Circumstances surrounding non-fatal opioid overdoses attended by ambulance services. Drug Alcohol Rev 2017;36:288–294.Google Scholar

CarlierL, Van Belleghem, V, Croes, K, Hooft, F. Gamma-hydroxybutyrate (GHB), an unusual cause of high anion gap metabolic acidosis. Can J Emerg Med 2018;20(S2):S2–S5.Google Scholar

Stefani M, , Roberts DM., 1,4-Butanediol overdose mimicking toxic alcohol exposure. Clin Toxicol 2020;58(3):204–207. https://doi.org/10.1080/15563650.2019.1617419Google Scholar

Wood, DM, Warren-Gash, C, Ashraf, T, et al. Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). QJM 2008;101:23–29.Google Scholar

Rambourg-Schepens, MO, Buffet, M, Durak, C, Mathieu-Nolf, M. Gamma-butyrolactone poisoning and its similarities to gamma-hydroxybutyric acid: two case reports. Vet Hum Toxicol 1997;39(4):234–235.Google Scholar

Knudsen, K, Greter, J, Verdicchio, M. High mortality rates among GHB abusers in Western Sweden. Clin Toxicol 2008;46:187–192.Google Scholar

Liechti, ME, Kunz, I, Greminger, P, Speich, R, Kupferschmidt, H. Clinical features of gamma-hydroxy-butyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend 2006;81:323–326.Google Scholar

Dietze, PM, Cvetkovski, S, Barratt, MJ, Clemens, S. Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria. Med J Aust 2008;188:709–711.Google Scholar

Theron, L, Jansen, K, New Zealand’s, Skinner A. first fatality linked to use of 1,4-butanediol (1,4-B, Fantasy): no evidence of coingestion or comorbidity. N Z Med J 2003;116:U650.Google Scholar

Couper, FJ, Thatcher, JE, Logan, BK. Suspected GHB overdoses in the emergency department. J Anal Toxicol 2004;28:481–484.Google Scholar

Roberts, DM, Smith, MW, Gopalakrishnan, M, Whittaker, G, Day, RO. Extreme gamma-butyrolactone overdose with severe metabolic acidosis requiring hemodialysis. Ann Emerg Med 2011;58:83–85.Google Scholar

Anderson, IB, Kim, SY, Dyer, JE, et al. Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003. Ann Emerg Med 2006;47:177–183.Google Scholar

Ryan, JM, Stell, I. Gamma hydroxybutyrate: a coma inducing recreational drug. J Accid Emerg Med 1997;14:259–291.Google Scholar

Centers for Disease Control and Prevention (CDC). Gamma hydroxy butyrate use – New York and Texas, 1995–1996. Morb Mortal Wkly Rep 1997;46:281–283.Google Scholar

Schneidereit, T, Burkhart, K, Donovan, JW. Butanediol toxicity delayed by preingestion of ethanol. Int J Med Toxicol 2000;3:1.Google Scholar

Zvosec, DL, Smith, SW, McCutcheon, JR, Spillane, J, Hall, BJ, Peacock, EA. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 2001;344:87–94.CrossRefGoogle ScholarPubMed

Centers for Disease Control and Prevention (CDC). Adverse events associated with ingestion of gamma-butyrolactone – Minnesota, New Mexico, and Texas, 1998–1999. Morb Mortal Wkly Rep 1999;48:137–140.Google Scholar

Stephens, BG, Baselt, RC. Driving under the influence of GHB? J Anal Toxicol 1994;18:357–358.Google Scholar

Al-Samarraie, MS, Karinen, R, Morland, J, Opdal, MS. Blood GHB concentrations and results of medical examinations in 25 car drivers in Norway. Eur J Clin Pharmacol 2010;66:987–998.Google Scholar

Ross, TM. Gamma hydroxybutyrate overdose: two cases illustrate the unique aspects of this dangerous recreational drug. J Emerg Nurs 1995;21:374–376.Google Scholar

Ortmann, LA, Jaeger, MW, James, LP, Schexnayder, SM. Coma in a 20-month-old child from an ingestion of a toy containing 1,4-butanediol, a precursor of gamma-hydroxybutyrate. Pediatr Emerg Care 2009;25:758–760.Google Scholar

Price, PA, Schachter, M, Smith, S, Baxter, RC, Parkes, JD. Gamma-hydroxybutyrate in narcolepsy. Ann Neurol 1981;9:198.Google Scholar

Couper, FJ, Logan, BK. Determination of gamma-hydroxybutyrate (GHB) in biological specimens by gas chromatography–mass spectrometry. J Anal Toxicol 2000;24:1–7.Google Scholar

Eckstein, M, Henderson, SO, DelaCruz, P, Newton, E. Gamma hydroxybutyrate (GHB): report of a mass intoxication and review of the literature. Prehosp Emerg Care 1999;3:357–361.Google Scholar

Bosman, IJ, Lusthof, KJ. Forensic cases involving the use of GHB in the Netherlands. Forensic Sci Int 2003;133:17–21.Google Scholar

Mégarbane, B, Fompeydie, D, Garnier, R, Baud, FJ. Treatment of a 4-butanediol poisoning with fomepizole. J Toxicol Clin Toxicol 2002;40:77–80.Google Scholar

Piastra, M, Tempera, A, Caresta, E, et al. Lung injury from ‘liquid ecstasy’: a role for coagulation activation? Pediatr Emerg Care 2006;22:358–360.Google Scholar

Gunja, N, Doyle, E, Carpenter, K, et al. Gamma-hydroxybutyrate poisoning from toy beads. Med J Aust 2008;188:54–55.Google Scholar

Hefele, B, Naumann, N, Trollmann, R, Dittrich, K, Rascher, W. Fast-in, fast-out. Lancet 2009;373:1398.Google Scholar

Ragg, M. Gamma hydroxy butyrate overdose. Emerg Med 1997;9:29–31.Google Scholar

Williams, H, Taylor, R, Roberts, M. Gamma-hydroxybutyrate (GHB): a new drug of misuse. Ir Med J 1998;91:56–57.Google Scholar

Dyer, JE. Gamma-hydroxybutyrate: a health-food product producing coma and seizure-like activity. Am J Emerg Med 1991;9:321–324.Google Scholar

Chin, MY, Kreutzer, RA, Dyer, JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992;156:380–384.Google Scholar

Viswanathan, S, Chen, C, Kolecki, P. Revivarant (gamma-butyrolactone) poisoning. Am J Emerg Med 2000;18:358–359.Google Scholar

Osterhoudt, KC, Henretig, FM. Comatose teenagers at a party: what a tangled ‘Web’ we weave. Pediatr Case Rev 2003;3:171–173.Google Scholar

Shannon, M, Quang, LS. Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature. Pediatr Emerg Care 2000;16:435–440.Google Scholar

Caldicott, DG, Kuhn, M. Gamma-hydroxybutyrate overdose and physostigmine: teaching new tricks to an old drug? Ann Emerg Med 2001;37:99–102.Google Scholar

Runnacles, JL, Stroobant, J. Gamma-hydroxybutyrate poisoning: poisoning from toy beads. BMJ 2008;336:110.Google Scholar

Yates, SW, Viera, AJ. Physostigmine in the treatment of gamma-hydroxybutyric acid overdose. Mayo Clin Proc 2000;75:401–402.Google Scholar

Libetta, C. Gamma hydroxybutyrate poisoning. J Accid Emerg Med 1997;14:411.Google Scholar

Savage, T, Khan, A, Loftus, BG. Acetone-free nail polish remover pads: toxicity in a 9-month-old. Arch Dis Child 2007;92:371.Google Scholar

Robert, R, Eugène, M, Frat, JP, Rouffineau, J. Diagnosis of unsuspected gamma hydroxy-butyrate poisoning by proton NMR. J Toxicol Clin Toxicol 2001;39:653–654.Google Scholar

Winickoff, JP, Houck, CS, Rothman, EL, Bauchner, H. Verve and jolt: deadly new Internet drugs. Pediatrics 2000;106:829–831.Google Scholar

Lenz, D, Rothschild, MA, Kroner, L. Intoxications due to ingestion of gamma-butyrolactone: organ distribution of gamma-hydroxybutyric acid and gamma-butyrolactone. Ther Drug Monit 2008;30:755–761.Google Scholar

Lora-Tamayo, C, Tena, T, Rodriguez, A, Sancho, JR, Molina, E. Intoxication due to 1,4-butanediol. Forensic Sci Int 2003;133:256–259.Google Scholar

Higgins, TFJ, Borron, SW. Coma and respiratory arrest after exposure to butyrolactone. J Emerg Med 1996;14:435–457.Google Scholar

Yambo, CM, McFee, RB, Caraccio, TR, McGuigan, M. The inkjet cleaner ‘Hurricane’ – another GHB recipe. Vet Hum Toxicol 2004;46:329–330.Google Scholar

Suner, S, Szlatenyi, CS, Wang, RY. Pediatric gamma hydroxybutyrate intoxication. Acad Emerg Med 1997;4:1041–1045.Google Scholar

Krul, J, Girbes, AR. Gamma-hydroxybutyrate: experience of 9 years of gamma-hydroxybutyrate (GHB)-related incidents during rave parties in the Netherlands. Clin Toxicol 2011;49:311–315.Google Scholar

Elliott, S. Nonfatal instances of intoxication with gamma-hydroxybutyrate in the United Kingdom. Ther Drug Monit 2004;26:432–440.Google Scholar

Tancredi, DN, Shannon, MW. Case records of the Massachusetts General Hospital. Weekly clinico-pathological exercises. Case 30-2003. A 21-year-old man with sudden alteration of mental status. N Engl J Med 2003;349:1267–1275.Google Scholar

Cisek, J. Seizure associated with butanediol ingestion. Int J Med Toxicol 2001;4:12.Google Scholar

Harraway, T, Stephenson, L. Gamma hydroxybutyrate intoxication: the Gold Coast experience. Emerg Med 1999;11:45–48.Google Scholar

Hardy, CJ, Slifman, NR, Klontz, KC, Dyer, JE, Coody, GL, Love, LA. Adverse events reported with the use of gamma butyrolactone products marketed as dietary supplements. Clin Toxicol 1999;37:649–650.Google Scholar

Mahon, KD, Tomaszewski, CA, Tayal, VS. Emergency department presentation of serum confirmed GHB ingestions. Acad Emerg Med 1999;6:395–396.Google Scholar

Vickers, MD. Gamma hydroxybutyric acid. Proc R Soc Med 1968;61:821–824.Google Scholar

Geldenhuys, FG, Sonnendecker, EW, De Kirk, MC. Experience with sodium-gamma-4-hydroxybutyric acid (gamma-OH) in obstetrics. J Obstet Gynaecol Br Commonw 1968;75(4):405–413.Google Scholar

Tunstall, ME. Gamma-OH in anesthesia for caesarean section. Proc R Soc Med 1968;61:827–830.Google Scholar

Laborit, H. Soduim 4-hydroxybutyrate. Int J Neuropharmacol 1964;3:433–445.Google Scholar

Piastra, M, Barbaro, R, Chiaretti, A, Tempera, A, Pulitanò, S, Polidori, G. Pulmonary oedema caused by ‘liquid ecstasy’ ingestion. Arch Dis Child 2002;86:302–303.Google Scholar

Jones, C. Suspicious death related to gamma-hydroxybutyrate (GHB) toxicity. J Clin Forensic Med 2001;8:74–76.Google Scholar

Doyon, S. The many faces of ecstasy. Curr Opin Pediatr 2001;13(6):170–176.Google Scholar

Bamonte, G, de Hoog, J, Van Den Biesen, PR. A case of central serous chorioretinopathy occurring after γ-hydroxybutyric acid (liquid ecstasy) ingestion. Retin Cases Brief Rep 2013;7(4):313–314. https://doi.org/10.1097/ICB.0b013e31828ef073Google Scholar

Garrison, G, Mueller, P. Clinical features and outcomes after unintentional gamma hydroxybutyrate (GHB) overdose. J Toxicol Clin Toxicol 1998;35:503–504.Google Scholar

Wood, DM, Brailsford, AD, Dargan, PI. Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal 2011;3(7–8):417–425. https://doi.org/10.1002/dta.292Google Scholar

Entholzner, E, Mielke, L, Pichlmeier, R, Weber, F, Schneck, H. EEG changes during sedation with gamma-hydroxybutyric acid. Anaesthesist 1995;44:345–350.Google Scholar

Okun, MS, Boothby, LA, Bartfield, RB, Doering, PL. GHB: an important pharmacological and clinical update. J Pharm Pharm Sci 2001;4(2):167–175.Google Scholar

Thai, D, Dyer, JE, Benowitz, NL, Haller, CA. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol 2006;26(5):524–529.Google Scholar

Department of Health. A Summary of the Health Harms of Drugs. Published August 2011.Google Scholar

Hammoud, MA, Bourne, A, Maher, L, et al. Intensive sex partying with gamma-hydroxybutyrate: factors associated with using gamma-hydroxybutyrate for chemsex among Australian gay and bisexual men – results from the Flux Study. Sex Health 2018;15(2):123–134. https://doi.org/10.1071/SH17146Google Scholar

Lettieri, J, Fung, HL. Absorption and first-pass metabolism of 14C-gamma-hydroxybutyric acid. Res Commun Chem Pathol Pharmacol 1976;13:425–437.Google Scholar

Harrington, RD, Woodward, JA, Hooton, TM, Horn, JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999;159(18):2221–2224.Google Scholar

Harrington, RD, Woodward, JA, Hooton, TM, Horn, JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999;159(18):2221–2224.CrossRefGoogle ScholarPubMed

Romanelli, F, Smith, KM, Pomeroy, C. Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men. Top HIV Med 2003;11(1):25–32.Google Scholar

Staltari, O, Leporini, C, Caroleo, B, et al. Drug-drug interactions: antiretroviral drugs and recreational drugs. Recent Pat CNS Drug Discov 2014;9:153–163.Google Scholar

Psichogiou M, , Poulakou G, , Basoulis D, , Paraskevis D, , Markogiannakis A, , Daikos GL. Recent advances in antiretroviral agents: potent integrase inhibitors. Curr Pharmaceut Des 2017;23:1–16.Google Scholar

Drogies T, , Willenberg A, , Ramshorn-Zimmer, A, et al. Detection of gamma hydroxybutyrate in emergency department: nice to have or a valuable diagnostic tool? Hum Exp Toxicol 2015;35(7):1–8.Google Scholar

Busardò FP, , Jones AW., GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol 2015;13(1):47–70.Google Scholar

LeTourneau, JL, Hagg, DS, Smith, SM. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care 2008;8(3):430–433. https://doi.org/10.1007/s12028-008-9062-2Google Scholar

LeTourneau, JL, Hagg, DS, Baclofen, Smith SM and gamma-hydroxybutyrate withdrawal. Neurocrit Care 2008;8(3):430–433.Google Scholar

Mason, PE, Kerns, WP. Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg Med 2002;9(7):730–739.Google Scholar

Busardò FP, , Jones AW., GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol 2015;13(1):47–70.Google Scholar

Thomas, G, Bonner, S, Gascoigne, A. Coma induced by abuse of gamma-hydroxybutyrate (GHB or liquid ecstasy): a case report. BMJ 1997;314:35–36.Google Scholar

Busardò FP, , Jones, AW. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol 2015;13(1)47–70.Google Scholar

Liechti, ME, Kupferschmidt, H. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL): analysis of overdose cases reported to the Swiss Toxicological Information Centre. Swiss Med Wkly 2004;134:534–537.Google Scholar

TOXBASE www.toxbase.org [accessed 3 February 2020].Google Scholar

TOXBASE www.toxbase.org [accessed 3 February 2020].Google Scholar

Busardò FP, , Jones AW., GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol 2015;13(1):47–70.Google Scholar

TOXBASE www.toxbase.org [accessed 3 February 2020].Google Scholar

Follman, KE, Morris, M. Treatment of gamma-hydroxybutyric acid and gamma-butyrolactone overdose with two potent monocarboxylate transporter 1 inhibitors, AZD3965 and AR-C155858. J Pharmacol Exp Ther 2019;370(1);84–91. https://doi.org/10.1124/jpet.119.256503Google Scholar

Nunez OF, Lopez, Rymer JA, , Tamama K., Case of sudden acute coma followed by spontaneous recovery. J Appl Lab Med 2018;3(3):507–510.Google Scholar

Reeves, J, Duda, R. GHB/GBL intoxication and withdrawal: a review and case presentation. Addict Disord Treatment 2003;2:25–28.Google Scholar

van Noordena MS, , Mol T, , Wisselink J, , Kuijpers W, , Boukje, AG. Dijkstra Treatment consumption and treatment re-enrollment in GHB-dependent patients in the Netherlands. Drug Alcohol Depend 2017;176:96–101.Google Scholar

Dyer, JE, Roth, B, Hyma, BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001;37:147–153.Google Scholar

Galloway, GP, Frederick, SL, Staggers, F. Physical dependence on sodium oxybate. Lancet 1994;343:57.Google Scholar

Wojtowicz, JM, Yarema, MC, Wax, PM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. CJEM 2008;10(1):69–74.Google Scholar

Kamal RM, , van Noorden MS, , Wannet W, , Beurmanjer H, , Dijkstra BAG, , Schellekens A. Pharmacological treatment in c-hydroxybutyrate (GHB) and c-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs 2017;31:51–64. https://doi.org/10.1007/s40263-016-0402-zGoogle Scholar

Kamal RM, , van Noorden MS, , Wannet W, , Beurmanjer H, , Dijkstra BAG, , Schellekens A. Pharmacological treatment in c-hydroxybutyrate (GHB) and c-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs 2017;31:51–64. https://doi.org/10.1007/s40263-016-0402-zGoogle Scholar

Wojtowicz, J. Withdrawal from gamma-hydroxybutyrate,1,4- butanediol and gamma-butyrolactone: a case report and systematic review. CJEM 2008;10(1):69–74.Google Scholar

Mahr, G, Bishop, CL, Orringer, DJ. Prolonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abuse. Psychosomatics 2001;42(5):439–440.Google Scholar

Kamal RM, , van Noorden MS, , Wannet W, , et al. Pharmacological treatment in c-hydroxybutyrate (GHB) and c-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs 2017;31:51–64. https://doi.org/10.1007/s40263-016-0402-zGoogle Scholar

Wood, DM, Dargan, PI. Development of a protocol for the management of acute gamma-hydroxy- butyrate (GHB) and gamma-butyrolactone (GBL) withdrawal. Clin Toxicol 2010;48:306.Google Scholar

Glasper, A, McDonough, M, Bearn, J. Within-patient variability in clinical presentation of gamma- hydroxybutyrate withdrawal: a case report. Eur Addict Res 2005;11(3):152–154.Google Scholar

Kamal RM, , van Noorden MS, , Wannet W, , Beurmanjer H, , Dijkstra BAG, , Schellekens A. Pharmacological treatment in c-hydroxybutyrate (GHB) and c-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs 2017;31:51–64. https://doi.org/10.1007/s40263-016-0402-zGoogle Scholar

Snead, OC. Gamma-hydroxybutyrate. Life Sci 1977;20:1935–1944.Google Scholar

van Noorden, MS, van Dongen, L, Zitman, FG, Vergouwen, T. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. Gen Hosp Psychiatry 2009;31:394–396.Google Scholar

Miglani, JS, Kim, KY, Chahil, R. Gamma-hydroxy butyrate withdrawal delirium: a case report. Gen Hosp Psychiatry 2000;22:213–215.Google Scholar

Hutto, B, Fairchild, A, Bright, R. Gamma-hydroxybutyrate withdrawal and chloral hydrate. Am J Psychiatry 2000;157:1706.Google Scholar

Hernandez, M, McDaniel, CH, Costanza, CD, Hernandez, OJ. GHB-induced delirium: a case report and review of the literature of gamma hydroxybutyric acid. Am J Drug Alcohol Abuse 1998;24:179–183.Google Scholar

Catalano, MC, Glass, JM, Catalano, G, Burrows, S, Lynn, W, Weitzner, BS. Gamma butyrolactone (GBL) withdrawal syndromes. Psychosomatics 2001;42:83–88.Google Scholar

Bowles, TM, Sommi, RW, Amiri, M. Successful management of prolonged gamma-hydroxybutyrate and alcohol withdrawal. Pharmacotherapy 2001;21:254–257.Google Scholar

Mahr, G, Bishop, CL, Orringer, DJ. Prolonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abuse. Psychosomatics 2001;42:439–440.Google Scholar

McDaniel, CH, Miotto, KA. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoactive Drugs 2001;33:143–149.Google Scholar

Schneir, AB, Ly, HT, Clark, RF. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. J Emerg Med 2001;21:31–33.Google Scholar

Perez, E, Chu, J, Bania, T. Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal. Ann Emerg Med 2006;48:219–220.Google Scholar

Zepf, FD, Holtmann, M, Duketis, E, et al. A 16-year-old boy with severe gamma-butyrolactone (GBL) withdrawal delirium. Pharmacopsychiatry 2009;42:202–203.Google Scholar

Bennett, WRM, Wilson, LG, Roy-Byrne, PP. Gamma-hydroxybutyric acid (GHB) withdrawal: a case report. J Psychoactive Drugs 2007;39:293–296.Google Scholar

Rosenberg, MH, Deerfield, LJ, Baruch, EM. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: recommendations for management. Am J Drug Alcohol Abuse 2003;29:487–496.Google Scholar

Friedman, J, Westlake, R, Furman, M. ‘Grievous bodily harm’: gamma hydroxybutyrate abuse leading to a Wernicke–Korsakoff syndrome. Neurology 1996;46:469–471.Google Scholar

Addolorato, G, Caputo, F, Capristo, E, Bernardi, IM, Stefanini, GF, Gasbarrini, G. A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: utility of diazepam administration. Clin Neuropharmacol 1999;22:60–62.Google Scholar

Mycyk, MB, Wilemon, C, Aks, SE. Two cases of withdrawal from 1,4-butanediol use. Ann Emerg Med 2001;38:345–346.Google Scholar

Price, G. In-patient detoxification after GHB dependence. Br J Psychiatry 2000;177:181.Google Scholar

Mullins, ME, Fitzmaurice, SC. Lack of efficacy of benzodiazepines in treating gamma-hydroxybutyrate withdrawal. J Emerg Med 2001;20:418–420.Google Scholar

Constantinides, P, Vincent, P. Chronic gamma-hydroxybutyric acid use followed by gamma-hydroxybutyric acid withdrawal mimic schizophrenia: a case report. Cases J 2009;2:7520. https://doi.org/10.4076/1757-1626-2-7520Google Scholar

Claussen, M, Hassanpour, K, Jenewein, J, Boettger, S. Catatonic stupor secondary to gamma-hydroxy-butyric acid (GHB)-dependence and -withdrawal syndrome. Psychiatria Danubina 2014;26(4):358–359.Google Scholar

Chien, J, Ostermann, G, Turkel, SB. Sodium oxybate-induced psychosis and suicide attempt in an 18-year-old girl. J Child Adolesc Psychopharmacol 2013;23(4):300–301.Google Scholar

Kamal, RM, Dijkstra, BAG, de Weert-van Oene, GH, van Duren, JAM, De Jong, CAJ. Psychiatric comorbidity, psychological distress and quality of life in gamma-hydroxybutyrate (GHB) dependent patients. J Addict Dis 2016 (online). https://doi.org/10.1080/10550887.2016.1214000Google Scholar

Kamal RM, , van Noorden MS, , Wannet W, , Beurmanjer H, , Dijkstra BAG, , Schellekens A. Pharmacological treatment in c-hydroxybutyrate (GHB) and c-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs 2017;31:51–64. https://doi.org/10.1007/s40263-016-0402-zGoogle Scholar

Kamal RM, , van Noorden MS, , Wannet W, , Beurmanjer H, , Dijkstra BAG, , Schellekens A. Pharmacological treatment in c-hydroxybutyrate (GHB) and c-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs 2017;31:51–64. https://doi.org/10.1007/s40263-016-0402-zGoogle Scholar

Constantinides P, Vincent P. Chronic gamma-hydroxybutyric-acid use followed by gamma-hydroxybutyric-acid withdrawal mimic schizophrenia: a case report. Cases J 2009;2:7520.Google Scholar

Kuiper MA, Peikert N, Boerma EC. Gamma-hydroxybutyrate withdrawal syndrome: a case report. Cases J 2009;2:6530. https://doi.org/10.1186/1757-1626-2-6530Google Scholar

Snead, O, Gibson, KM. g-hydroxybutyric acid. N Engl J Med 2005;352(26):2721–2732.Google Scholar

Freese, TE, Miotto, K, Reback, CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat 2002;23(2):151–156.Google Scholar

Domınguez, Bruguera, I Balcells-Olivero´, P Batalla A., M Depression following c-hydroxybutyrate withdrawal: a case report. J Clin Psychopharmacol 2015;35(5):618–619.Google Scholar

Miotto, K, Darakjian, J, Basch, J, Murray, S, Zogg, J, Rawson, R. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001;10(3):232–241.Google Scholar

Heiligenberg, M, Wermeling, PR, van Rooijen, MS, et al . Recreational drug use during sex and sexually transmitted infections among clients of a city sexually transmitted infections clinic in Amsterdam, the Netherlands. Sex Transm Dis 2012;39(7):518–527. https://doi.org/10.1097/OLQ.0b013e3182515601Google Scholar

Carey, JW, Mejia, R, Bingham, T, et al. Drug use, high-risk sex behaviors, and increased risk for recent HIV infection among men who have sex with men in Chicago and Los Angeles. AIDS Behav 2009;13(6):1084–1096. https://doi.org/10.1007/s10461-008-9403-3Google Scholar

Grov, C, Parsons, JT, Bimbi, DS, Sex and Love v3.0 Research Team. In the shadows of a prevention campaign: sexual risk behavior in the absence of crystal methamphetamine. AIDS Educ Prev 2008;20(1):42–55. https://doi.org/10.1521/aeap.2008.20.1.42Google Scholar

Liao P-C, , Chang H-M, , Chen Y-L., Clinical management of gamma-hydroxybutyrate (GHB) withdrawal delirium with CIWA-Ar protocol. J Formos Med Assoc 2018;117(12):1124–1127.Google Scholar

Handelsman, L, Cochrane, KJ, Aronson, MJ, Ness, R, Rubinstein, KJ, Kanof, PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987;13:293–308.Google Scholar

Winstock, AR, Mitcheson, L. New recreational drugs and the primary care approach to patients who use them. Br Med J 2012;344:e288. https://doi.org/10.1136/bmj.e288Google Scholar

Kamal RM, , van Noorden MS, , Wannet W, , Beurmanjer H, , Dijkstra BAG, , Schellekens A. Pharmacological treatment in c-hydroxybutyrate (GHB) and c-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs 2017;31:51–64. https://doi.org/10.1007/s40263-016-0402-zGoogle Scholar

van Mechelen, JC, Dijkstra, BAG, Vergouwen, ACM. Severe illicit gamma-hydroxybutyric acid withdrawal in a pregnant woman: what to do? BMJ Case Rep 2019;12:e230997. https://doi.org/10.1136/bcr-2019-230997Google Scholar

www.toxbase.org/poisons-index-a-z/g-products/ghb-and-analogues/ [last accessed 23 February 2022].Google Scholar

Craig, K, Gomez, HF, McManus, JL, Bania, T. Sever gamma-hydroxybutyrate witdrawal: a case report and literature review. J Emerg Med 2000;18(1):65–70.Google Scholar

McDonough, M, Kennedy, N, Glasper, A, Bearn, J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004;75(1):3–9.Google Scholar

McDaniel, C, Miotto, KA. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoactive Drugs 2001;33:143–149.Google Scholar

de Jong, C, Kamal, R, Dijkstra, BA, de Haan, HA. Gamma-hydroxybutyrate detoxification by titration and tapering. Eur Addict Res 2012;18(1):40–45.Google Scholar

Chin, R. A case of severe withdrawal from gamma-hydroxybutyrate. Ann Emerg Med 2001;37(5):551–552.Google Scholar

van Mechelen JC, Dijkstra BAG, Vergouwen ACM. Severe illicit gamma-hydroxybutyric acid withdrawal in a pregnant woman: what to do? BMJ Case Rep 2019;12:e230997. https://doi.org/10.1136/bcr-2019-230997Google Scholar

Floyd CN, , Wood DM, , Darganm PI. Baclofen in gamma-hydroxybutyrate withdrawal: patterns of use and online availability. Eur J Clin Pharmacol 2018;74:349–356. https://doi.org/10.1007/s00228-017-2387-zGoogle Scholar

Beurmanjer H, , Kamal RM, , de Jong CAJ, , Dijkstra BAG, , Schellekens AFA. Baclofen to prevent relapse in gamma-hydroxybutyrate (GHB)-dependent patients: a multicentre, open-label, non-randomized, controlled trial. CNS Drugs 2018;32:437–442. https://doi.org/10.1007/s40263-018-0516-6Google Scholar

Lingford-Hughes, A, Patel, Y, Bowden-Jones, O, et al. Improving GHB withdrawal with baclofen: study protocol for a feasibility study for a randomised controlled trial. Trials 2016;17:472. https://doi.org/10.1186/s13063-016-1593-9Google Scholar

Beurmanjer H, , Kamal RM, , de Jong CAJ, , Dijkstra BAG, , Schellekens AFA. Baclofen to prevent relapse in gamma-hydroxybutyrate (GHB)-dependent patients: a multicentre, open-label, non-randomized, controlled trial. CNS Drugs 2018;32:437–442. https://doi.org/10.1007/s40263-018-0516-6Google Scholar

Habibian S, , Ahamad K, , McLean M, , Socias M., Successful management of gamma-hydroxybutyrate (GHB) withdrawal using baclofen as a standalone therapy: a case report. J Addiction Med 2019;13(5):415–417. https://doi.org/10.1097/ADM.0000000000000514Google Scholar

Beurmanjer H, , Kamal RM, , de Jong CAJ, , Dijkstra BAG, , Schellekens AFA. Baclofen to prevent relapse in gamma-hydroxybutyrate (GHB)-dependent patients: a multicentre, open-label, non-randomized, controlled trial. CNS Drugs 2018;32:437–442. https://doi.org/10.1007/s40263-018-0516-6Google Scholar

Dijkstra BAG, Kamal R, van Noorden MS, , de Haan H, , Loonen AJM, , De Jong CAJ. Detoxification with titration and tapering in gamma-hydroxybutyrate (GHB) dependent patients: the Dutch GHB monitor project. Drug Alcohol Depend 2017;170164–170173. https://doi.org/10.1016/j.drugalcdep.2016.11.014Google Scholar

Kamal, RM, van Noorden, MS, Wannet, W, et al. Pharmacological treatment in c-hydroxybutyrate (GHB) and c-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs 2017;31:51–64. https://doi.org/10.1007/s40263-016-0402-zGoogle Scholar

Beurmanjer H, , Kamal RM, , de Jong CAJ, , Dijkstra BAG, , Schellekens AFA. Baclofen to prevent relapse in gamma-hydroxybutyrate (GHB)-dependent patients: a multicentre, open-label, non-randomized, controlled trial. CNS Drugs 2018;32:437–442. https://doi.org/10.1007/s40263-018-0516-6Google Scholar

Lingford-Hughes, A, Patel, Y, Bowden-Jones, O, et al. Improving GHB withdrawal with baclofen: study protocol for a feasibility study for a randomised controlled trial. Trials 2016;17:472. https://doi.org/10.1186/s13063-016-1593-9Google Scholar

Beurmanjer H, , Kamal RM, , de Jong CAJ, , Dijkstra BAG, , Schellekens AFA. Baclofen to prevent relapse in gamma-hydroxybutyrate (GHB)-dependent patients: a multicentre, open-label, non-randomized, controlled trial. CNS Drugs 2018;32:437–442. https://doi.org/10.1007/s40263-018-0516-6Google Scholar

Beurmanjer H, , Kamal RM, , de Jong CAJ, , Dijkstra BAG, , Schellekens AFA. Baclofen to prevent relapse in gamma-hydroxybutyrate (GHB)-dependent patients: a multicentre, open-label, non-randomized, controlled trial. CNS Drugs 2018;32:437–442. https://doi.org/10.1007/s40263-018-0516-6Google Scholar

Beurmanjer H, , Kamal RM, , de Jong CAJ, , Dijkstra BAG, , Schellekens AFA. Baclofen to prevent relapse in gamma-hydroxybutyrate (GHB)-dependent patients: a multicentre, open-label, non-randomized, controlled trial. CNS Drugs 2018;32:437–442. https://doi.org/10.1007/s40263-018-0516-6Google Scholar

Habibian S, , Ahamad K, , McLean M, , Socias, M. Successful management of gamma-hydroxybutyrate (GHB) withdrawal using baclofen as a standalone therapy: a case report. J Addict Med 2019;13(5):415–417.Google Scholar

Beurmanjer H, , Kamal RM, , de Jong CAJ, , Dijkstra BAG, , Schellekens AFA. Baclofen to prevent relapse in gamma-hydroxybutyrate (GHB)-dependent patients: a multicentre, open-label, non-randomized, controlled trial. CNS Drugs 2018;32:437–442. https://doi.org/10.1007/s40263-018-0516-6Google Scholar

Addolorato, G, Caputo, F, Capristo, E, et al. Diazepam in the treatment of GHB dependence. Br J Psychiatry 2001;178:183 (letter).Google Scholar

Dyer, JE, Andrews, KM. Gamma hydroxybutyrate withdrawal. J Toxicol Clin Toxicol 1997;35:553–554.Google Scholar

Eiden, C, Capdevielle, D, Deddouche, C, Boulenger, JP, Blayac, JP, Peyrière, H. Neuroleptic malignant syndrome-like reaction precipitated by antipsychotics in a patient with gamma-butyrolactone withdrawal. J Addict Med 2011;5(4):302–303. https://doi.org/10.1097/ADM.0b013e3182236730Google Scholar

Veerman Selene ATE, , Veerman RT. Current developments regarding GHB and GBL incidents, treatment and detection: a qualitative review. World J Pharm Res 2019;8(7):11–26.Google Scholar

Floyd CN, , Wood DM, , Dargan PI. Baclofen in gamma-hydroxybutyrate withdrawal: patterns of use and online availability. Eur J Clin Pharmacol 2018;74:349–356. https://doi.org/10.1007/s00228-017-2387-zGoogle Scholar

Kamal, RM, Qurishi, R, De Jong, CA. Baclofen and γ-hydroxybutyrate (GHB), a dangerous combination. J Addict Med 2015;9(1):75–77. https://doi.org/10.1097/ADM.0000000000000084Google Scholar

de Jong, C, Kamal, R, Dijkstra, BA, de Haan, HA. Gamma-hydroxybutyrate detoxification by titration and tapering. Eur Addict Res 2012;18(1):40–45.Google Scholar

van Raay, MEJ. GHB-onttrekkingsverschijnselen behandeled met diazepam, baclofen en propranolol. Psyfar 2012;2:22–25.Google Scholar

Bell, J, Gamma-butyrolactone, Collins R. (GBL) dependence and withdrawal. Addiction 2011;106(2):442–447.Google Scholar

de Weert-van Oene, GH, Schellekens, AF, Dijkstra, BA, Kamal, R, de Jong, CA. Detoxification of patients with GHB dependence. Tijdschr Psychiatr Dutch 2013;55(11):885–890.Google Scholar

Stalcup, J, Wylie, B, Stalcup, SA. Outpatient treatment for GHB dependence. In: T Porrata, , ed. “ G’d Up” 24/7: The GHB Addiction Guide. Sam Clemente, CA: LawTech Publishing, 2007.Google Scholar

Kamal, RM, van Noorden, MS, Wannet, W, Beurmanjer, H, Dijkstra, BA, Schellekens, A. Pharmacological treatment in γ-hydroxybutyrate (GHB) and γ-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs 2017;31(1):51–64.Google Scholar

Kamal, RM, van Noorden, MS, Wannet, W, Beurmanjer, H, Dijkstra, BA, Schellekens, A. Pharmacological treatment in γ-hydroxybutyrate (GHB) and γ-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs 2017;31(1):51–64.Google Scholar

McDonough, M, Kennedy, N, Glasper, A, Bearn, J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004;75(1):3–9.Google Scholar

Kamal, RM, van Iwaarden, S, Dijkstra, BA, de Jong, CA. Decision rules for GHB (c-hydroxybutyric acid) detoxification: a vignette study. Drug Alcohol Depend 2014;135:146–151.Google Scholar

Kamal, R, De Jong, CAJ. Practice-Based Recommendations for the Detoxification of Patients with GHB Abuse Disorders in an Outpatient Setting. Nijmegen, Nijmegen Institute for Scientist Practitioners in Addiction (NISPA), 2013.Google Scholar

McDonough, M, Kennedy, N, Glasper, A, Bearn, J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004;75(1):3–9.Google Scholar

McDonough, M, Kennedy, N, Glasper, A, Bearn, J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004;75(1):3–9.Google Scholar

Bell, J, Gamma-butyrolactone, Collins R. (GBL) dependence and withdrawal. Addiction 2011;106(2):442–447.Google Scholar

McDonough, M, Kennedy, N, Glasper, A, Bearn, J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004;75(1):3–9.Google Scholar

Ghio, L, Cervetti, A, Respino, M, Belvederi Murri, M, Amore, M. Management and treatment of gamma butyrolactone withdrawal syndrome: a case report and review. J Psychiatr Pract 2014;20(4):294–300.Google Scholar

Project GHB. 2002.Google Scholar

Zepf, FD, Holtmann, M, Duketis, E, et al. Withdrawal syndrome after abuse of GHB (gamma-hydroxybutyrate) and its physiological precursors – its relevance for child and adolescent psychiatrists. Z Kinder Jugendpsychiatr Psychother 2009;37(5):413–420. https://doi.org/10.1024/1422-4917.37.5.413Google Scholar

Kamal, RM, Iwaarden, S Jong, CAJ. Decision rules for GHB (gamma-hydroxybutyric acid) detoxification: a vignette study.Google ScholarGoogle Scholar

Dijkstra, B, De Weert-van Oene, GH, Verbrugge, CAG, De Jong, C. End report GHB detoxification with pharmaceutical GHB DeTiTap monitor, in the Netherlands addiction care. Nijmegen, Nijmegen Institute for Scientist-Practitioners in Addiction, 2013.Google Scholar

Cappetta, M, Murnion, BP. In-patient management of gamma-hydroxybutyrate withdrawal. Australas Psychiatry 2019;27(3):284–287. https://doi.org/10.1177/1039856218822748Google Scholar

van Noordena MS, , Mol T, , Wisselink J, , Kuijpers W, , Dijkstra BAG. Treatment consumption and treatment re-enrollment in GHB-dependent patients in the Netherlands. Drug Alcohol Depend 2017;176:96–101.Google Scholar

Dijkstra, BAG, DeWeert-Van Oene, GH, Verbrugge, CAG, De Jong, CAJ. GHB-Detoxification Using Pharmaceutical GHB; Report from DeTiTap®-Monitoring in Dutch Addiction Care. NISPA, Nijmegen, The Netherlands, 2013.Google Scholar

Beurmanjer, H, Verbrugge, CAG, Schrijen, S, Schellekens, AFA, De Jong, CAJ, Dijkstra, BAG. Treatment of GHB-Dependence after Detoxification; Report NISPA GHB Monitor 2.0. NISPA, Nijmegen, The Netherlands.Google Scholar

Beurmanjer, H, Asperslag, EM, Verbrugge, CAG, et al. GHB-Dependence: Disease Perceptions and Need for Treatment. NISPA, Nijmegen, The Netherlands.Google Scholar

van Noordena MS, , Mol T, , Wisselink J, , Kuijpers W, , Dijkstra BAG. Treatment consumption and treatment re-enrollment in GHB-dependent patients in the Netherlands. Drug Alcohol Depend 2017;176:96–101.Google Scholar

Busardò, FP, Varì MR, , Di Trana A, , Malaca S, , Carlier J, , Di Luca NM., Drug-facilitated sexual assaults (DFSA): a serious underestimated issue. Eur Rev Med Pharmacol Sci 2019;23:10577–10587.Google Scholar

Németh, Z, Kun, B, Demetrovics, Z. The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review. J Psychopharmacol 2010;24(9):1281–1287.Google Scholar

Veerman ATE, , Veerman SRT. Current developments regarding GHB and GBL incidents, treatment and detection: a qualitative review. World J Pharm Res (online) 2019;8(7). www.researchgate.net/profile/Selene-Veerman/publication/333565737Google Scholar

Pettigrew, M. Somnophilia and sexual abuse through the administration of GHB and GBL. J Forensic Sci 2019;64(1). https://doi.org/10.1111/1556-4029.13812Google Scholar

Bracchi, M, Stuart, D, Castles, R, Khoo, S, Back, D, Boffito, M. Increasing use of ‘party drugs’ in people living with HIV on antiretrovirals: a concern for patient safety. Aids 2015;29(13):1585–1592.Google Scholar

Jones, AW, Holmgren, A, Kugelberg, FC. Driving under the influence of gamma-hydroxybutyrate (GHB). Forensic Sci Med Pathol 2008;4(4):205–211. https://doi.org/10.1007/s12024-008-9040-1Google Scholar